Summary:
- The article discusses a novel computational pathology-based TROP2 biomarker that was found to be predictive of clinical outcomes in patients with non-small cell lung cancer (NSCLC) treated with the antibody-drug conjugate datopotamab deruxtecan.
- The TROP2 biomarker was assessed using a computational pathology approach, which allowed for the quantification of TROP2 expression in tumor samples.
- The study showed that higher levels of TROP2 expression were associated with better clinical outcomes, including longer progression-free survival and overall survival, in NSCLC patients treated with datopotamab deruxtecan.